Diet, HealthyNCT07564674
Investigating the Bioavailability of Broccoli Extract Supplements
A study testing Avmacol Extra Strength with coating - 1 tablet, Avmacol chewable wafer - 2 tablets and Avmacol Extra Strength with coating - 2 tablets in people with Diet, Healthy, run by Oregon State University at 1 site in United States.
Trial summary
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Diet, Healthy
- What is being tested?
- Avmacol Extra Strength with coating - 1 tablet, Avmacol chewable wafer - 2 tablets and Avmacol Extra Strength with coating - 2 tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Aug 2026to Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults, 18-60 years of age
- Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
- Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
- Must be able to give written informed consent
Who cannot join
- Body Mass Index (BMI) <18.5 or >30.0 kg/m2
- Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
- Pregnancy, breastfeeding, or planning to become pregnant before completing the study
- Engaging in vigorous exercise more than 7 hours per week
- Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
- Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
Show all 10Show fewer
- Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
- Allergic to broccoli, moringa, mustard, or maitake mushrooms
- Weighs less than 110 pounds
- Diagnosis of sickle cell disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Oregon State University
Corvallis, Oregon, 97331
Sandra Uesugi, RN, BSN, MS, 541-737-3594, sandra.uesugi@oregonstate.edu
Emily Ho, PhD
About this study
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
Participants will:
- consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
- complete 3 separate 24 hour study cycles
- submit blood and urine samples for 24 hours
- follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)
Read the detailed description
This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. The amount of glucoraphanin that subjects will take will range from 35-70 mg. Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).
- Conditions
- Diet, Healthy
- Being tested
- Avmacol Extra Strength with coating - 1 tablet, Avmacol chewable wafer - 2 tablets, Avmacol Extra Strength with coating - 2 tablets
- Keywords
- cruciferous vegetable, broccoli extract supplement, glucoraphanin, sulforaphane
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Avmacol Extra Strength with coating - 1 tabletDietary supplement
Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
Avmacol chewable wafer - 2 tabletsDietary supplement
Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)
Avmacol Extra Strength with coating - 2 tabletsDietary supplement
Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
| Study group | Role | What they receive |
|---|---|---|
| 35 mg glucoraphanin | Active comparator | Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating. Receives: Dietary Supplement: Avmacol Extra Strength with coating - 1 tablet |
| 60 mg glucoraphanin | Active comparator | Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each) Receives: Dietary Supplement: Avmacol chewable wafer - 2 tablets |
| 70 mg glucoraphanin | Active comparator | Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each) Receives: Dietary Supplement: Avmacol Extra Strength with coating - 2 tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Urine sulforaphane
Change from baseline levels of sulforaphane in urine
Measured: 0, 2, 4, 8, and 24 hours
Urine sulforaphane metabolites
Change from baseline levels of sulforaphane in urine
Measured: 0, 2, 4, 8, and 24 hours
Plasma glucoraphanin
Change from baseline levels of plasma glucoraphanin
Measured: 0, 1, 2, 4, 8, and 24 hours
Plasma sulforaphane
Change from baseline levels of plasma sulforaphane
Measured: 0, 1, 2, 4, 8, and 24 hours
Plasma sulforaphane metabolites
Change from baseline levels of plasma sulforaphane metabolites
Measured: 0, 1, 2, 4, 8, and 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start4 Aug 2026
- Primary completionSep 2027 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diet, HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oregon State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emily Ho, Oregon State University
- Investigators
- Emily Ho, PhD, Principal investigator, Oregon State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07564674
- Sponsor's protocol ID
- LPI-2026-2211
- Status last verified
- Aug 2026
- First submitted
- 27 Apr 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We will not share IPD.
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Bioavailability of Broccoli Extract Supplements
- ClinicalTrials.gov ID
- NCT07564674
- Acronym / sponsor ID
- LPI-2026-2211
- Conditions
- Diet, Healthy
- Keywords
- cruciferous vegetable, broccoli extract supplement, glucoraphanin, sulforaphane
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Oregon State UniversityUniversity, hospital or other
- Study start
- 4 Aug 2026 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
Participants will:
- consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
- complete 3 separate 24 hour study cycles
- submit blood and urine samples for 24 hours
- follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)
Detailed description
This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. The amount of glucoraphanin that subjects will take will range from 35-70 mg. Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 35 mg glucoraphanin | Active comparator | Dietary Supplement: Avmacol Extra Strength with coating - 1 tabletParticipants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating. |
| 60 mg glucoraphanin | Active comparator | Dietary Supplement: Avmacol chewable wafer - 2 tabletsParticipants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each) |
| 70 mg glucoraphanin | Active comparator | Dietary Supplement: Avmacol Extra Strength with coating - 2 tabletsParticipants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy adults, 18-60 years of age
- Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
- Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
- Must be able to give written informed consent
Key exclusion criteria (10 listed)
- Body Mass Index (BMI) <18.5 or >30.0 kg/m2
- Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
- Pregnancy, breastfeeding, or planning to become pregnant before completing the study
- Engaging in vigorous exercise more than 7 hours per week
- Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Avmacol Extra Strength with coating - 1 tabletParticipants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet) | Dietary supplement | 35 mg glucoraphanin |
| Avmacol chewable wafer - 2 tabletsParticipants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer) | Dietary supplement | 60 mg glucoraphanin |
| Avmacol Extra Strength with coating - 2 tabletsParticipants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet) | Dietary supplement | 70 mg glucoraphanin |
Primary outcome
Urine sulforaphane
Time frame: 0, 2, 4, 8, and 24 hours
Change from baseline levels of sulforaphane in urine
Urine sulforaphane metabolites
Time frame: 0, 2, 4, 8, and 24 hours
Change from baseline levels of sulforaphane in urine
Plasma glucoraphanin
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma glucoraphanin
Plasma sulforaphane
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma sulforaphane
Plasma sulforaphane metabolites
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma sulforaphane metabolites
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: No. We will not share IPD.
Related trials for Diet, Healthy
Not yet recruiting
Optimal Defaults Grocery Shopping Intervention to Promote Healthy Diets for Pediatric Cancer Survivors and Their Families
Pediatric
Recruiting
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Microbiome
Not yet recruiting
Testing a Smartphone App to Support a Mediterranean Diet and Strength Exercise
Treatment Adherence and Compliance, Resistance Exercise
Active, not recruiting
Growing Healthy Children and Families in Rural Arkansas
Pediatric Obesity, Health Behavior, Risky
Not yet recruiting
Nutrition Intervention for Older Adults and Research Training
Impaired Mobility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Emily Ho, PhD principal investigator
Oregon State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Avmacol Extra Strength with coating - 1 tablet, Avmacol chewable wafer - 2 tablets and Avmacol Extra Strength with coating - 2 tablets in people with Diet, Healthy, run by Oregon State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emily Ho, PhD (541-737-9559, emily.ho@oregonstate.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Urine sulforaphane (time frame: 0, 2, 4, 8, and 24 hours). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.